España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Fulcrum Therapeutics
FULC
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$3.96
-0.22
-5.26%
At close: -
$3.96
0.00
0.00%
After Hours: Jan 31, 4:01 PM EDT
Get Report
Comment
Fulcrum Therapeutics (FULC) Forecast
News
Earnings
Fulcrum Therapeutics (FULC) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Fulcrum Therapeutics (NASDAQ:FULC) Stock
Fulcrum Therapeutics Stock (NASDAQ: FULC)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, December 23, 2024
Shares Of Fulcrum Therapeutics See Volume; Tr...
Benzinga Newsdesk
Thursday, November 14, 2024
RBC Capital Reiterates Sector Perform on Fulc...
Benzinga Newsdesk
Expert Ratings For Fulcrum Therapeutics
Benzinga Insights
HC Wainwright & Co. Reiterates Neutral on Ful...
Benzinga Newsdesk
Wednesday, November 13, 2024
Fulcrum Therapeutics Q3 2024 GAAP EPS $(0.35)...
Benzinga Newsdesk
Earnings Scheduled For November 13, 2024
Benzinga Insights
Tuesday, November 12, 2024
Earnings Preview: Fulcrum Therapeutics
Benzinga Insights
Fulcrum Therapeutics's Earnings Outlook
Benzinga Insights
Wednesday, October 02, 2024
IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag
Zacks
Friday, September 27, 2024
SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324
Zacks
Thursday, September 26, 2024
Fulcrum Therapeutics shares are trading highe...
Benzinga Newsdesk
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
Tuesday, September 24, 2024
Fulcrum Plans To Reduce Its Workforce From 80...
Benzinga Newsdesk
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal
Zacks
Friday, September 20, 2024
VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis
Zacks
Friday, September 13, 2024
FULC Stock Falls as Muscle Disorder Study Misses Primary Goal
Zacks
Fulcrum Therapeutics shares are trading lower...
Benzinga Newsdesk
RBC Capital Downgrades Fulcrum Therapeutics t...
Benzinga Newsdesk
Breaking Down Fulcrum Therapeutics: 7 Analysts Share Their Views
Benzinga Insights
HC Wainwright & Co. Downgrades Fulcrum Therap...
Benzinga Newsdesk
Thursday, September 12, 2024
Leerink Partners Downgrades Fulcrum Therapeut...
Benzinga Newsdesk
Dow Surges Over 100 Points; ModivCare Shares Plummet
Avi Kapoor
B of A Securities Downgrades Fulcrum Therapeu...
Benzinga Newsdesk
Stifel Downgrades Fulcrum Therapeutics to Hol...
Benzinga Newsdesk
Crude Oil Surges 3%; Kroger Posts Upbeat Earnings
Avi Kapoor
Fulcrum Therapeutics Suspends Rare Muscular Disease Candidate After Disappointing Data From Pivotal Trial
Vandana Singh
Cantor Fitzgerald Downgrades Fulcrum Therapeu...
Benzinga Newsdesk
US Stocks Mixed; Producer Prices Increase In August
Avi Kapoor
Market-Moving News for September 12th
Benzinga Newsdesk
Fulcrum Therapeutics shares are trading lower...
Benzinga Newsdesk
Fulcrum To Suspend Future Losmapimod Developm...
Benzinga Newsdesk
Fulcrum Therapeutics' Phase 3 REACH Trial Of ...
Benzinga Newsdesk
Monday, September 09, 2024
Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease
Vandana Singh
IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab
Zacks
B of A Securities Upgrades Fulcrum Therapeuti...
Benzinga Newsdesk
Friday, September 06, 2024
FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up
Zacks
Tuesday, September 03, 2024
Corcept Shares Rise More Than 45% in Six Months: Here's Why
Zacks
ALNY Down Despite Positive Data From Heart Disease Drug Study
Zacks
Tuesday, August 20, 2024
Mirum Banks on Livmarli, Overdependence a Concern
Zacks
Monday, August 19, 2024
AN2 Therapeutics Plunges 66% in a Month: Here's Why
Zacks
Friday, August 09, 2024
Novavax Lags on Q2 Earnings & Sales, Cuts '24 Outlook
Zacks
Thursday, August 08, 2024
SpringWorks Q2 Earnings Beat, Ogsiveo Drives Revenues
Zacks
Thursday, August 01, 2024
8 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Fulcrum...
Benzinga Newsdesk
Wednesday, July 31, 2024
Fulcum Therapeutics shares are trading higher...
Benzinga Newsdesk
Fulcrum Therapeutics Q2 EPS Totals $0.87 Comp...
Benzinga Newsdesk
Tuesday, July 16, 2024
Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter
Avi Kapoor
Wednesday, July 10, 2024
Cantor Fitzgerald Reiterates Overweight on Fu...
Benzinga Newsdesk
Tuesday, June 11, 2024
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights
Monday, May 20, 2024
Cantor Fitzgerald Initiates Coverage On Fulcr...
Benzinga Newsdesk
Show More